海南医学
海南醫學
해남의학
HAINAN MEDICAL JOURNAL
2015年
15期
2202-2204
,共3页
血脂异常%辛伐他汀%糖代谢
血脂異常%辛伐他汀%糖代謝
혈지이상%신벌타정%당대사
Dyslipidemia%Simvastatin%Glucose metabolism
目的：探讨不同剂量辛伐他汀治疗对血脂异常患者糖代谢的影响。方法选择2014年1~8月来我院接受治疗的血脂异常患者120例，按照数表法随机平均分为A、B、C三组，每组各40例，其中A组患者每天使用辛伐他汀10 mg ，B组患者为20 mg ，C组患者为40 mg ，治疗3个月后比较三组患者治疗后的血脂水平变化和糖代谢情况。结果①A、B、C三组患者治疗后的低密度脂蛋白胆固醇(LDL-C)分别为(2.83±0.52) mmol/L、(2.72±0.49) mmol/L和(1.71±0.32) mmol/L，差异有统计学意义(P<0.05)；高密度脂蛋白胆固醇(HDL-C)分别为(1.26±0.43) mmol/L、(1.32±0.47) mmol/L、(1.36±0.51) mmol/L，差异有统计学意义(P<0.05)；总胆固醇(TC)分别为(4.71±0.40) mmol/L、(4.32±0.31) mmol/L、(3.65±0.35) mmol/L，差异有统计学意义(P<0.05)；甘油三酯(TG)分别为(1.89±0.63) mmol/L、(1.85±0.61) mmol/L、(1.67±0.29) mmol/L，差异有统计学意义(P<0.05)；②治疗后三组患者的糖化血红蛋白与餐前及餐后血糖均轻微升高，胰岛素水平无明显变化，经比较差异均无统计学意义(P>0.05)。结论将辛伐他汀应用于血脂异常患者，剂量与疗效密切相关，较大剂量辛伐他汀具有高效性，但不同剂量辛伐他汀对糖代谢无明显影响。
目的：探討不同劑量辛伐他汀治療對血脂異常患者糖代謝的影響。方法選擇2014年1~8月來我院接受治療的血脂異常患者120例，按照數錶法隨機平均分為A、B、C三組，每組各40例，其中A組患者每天使用辛伐他汀10 mg ，B組患者為20 mg ，C組患者為40 mg ，治療3箇月後比較三組患者治療後的血脂水平變化和糖代謝情況。結果①A、B、C三組患者治療後的低密度脂蛋白膽固醇(LDL-C)分彆為(2.83±0.52) mmol/L、(2.72±0.49) mmol/L和(1.71±0.32) mmol/L，差異有統計學意義(P<0.05)；高密度脂蛋白膽固醇(HDL-C)分彆為(1.26±0.43) mmol/L、(1.32±0.47) mmol/L、(1.36±0.51) mmol/L，差異有統計學意義(P<0.05)；總膽固醇(TC)分彆為(4.71±0.40) mmol/L、(4.32±0.31) mmol/L、(3.65±0.35) mmol/L，差異有統計學意義(P<0.05)；甘油三酯(TG)分彆為(1.89±0.63) mmol/L、(1.85±0.61) mmol/L、(1.67±0.29) mmol/L，差異有統計學意義(P<0.05)；②治療後三組患者的糖化血紅蛋白與餐前及餐後血糖均輕微升高，胰島素水平無明顯變化，經比較差異均無統計學意義(P>0.05)。結論將辛伐他汀應用于血脂異常患者，劑量與療效密切相關，較大劑量辛伐他汀具有高效性，但不同劑量辛伐他汀對糖代謝無明顯影響。
목적：탐토불동제량신벌타정치료대혈지이상환자당대사적영향。방법선택2014년1~8월래아원접수치료적혈지이상환자120례，안조수표법수궤평균분위A、B、C삼조，매조각40례，기중A조환자매천사용신벌타정10 mg ，B조환자위20 mg ，C조환자위40 mg ，치료3개월후비교삼조환자치료후적혈지수평변화화당대사정황。결과①A、B、C삼조환자치료후적저밀도지단백담고순(LDL-C)분별위(2.83±0.52) mmol/L、(2.72±0.49) mmol/L화(1.71±0.32) mmol/L，차이유통계학의의(P<0.05)；고밀도지단백담고순(HDL-C)분별위(1.26±0.43) mmol/L、(1.32±0.47) mmol/L、(1.36±0.51) mmol/L，차이유통계학의의(P<0.05)；총담고순(TC)분별위(4.71±0.40) mmol/L、(4.32±0.31) mmol/L、(3.65±0.35) mmol/L，차이유통계학의의(P<0.05)；감유삼지(TG)분별위(1.89±0.63) mmol/L、(1.85±0.61) mmol/L、(1.67±0.29) mmol/L，차이유통계학의의(P<0.05)；②치료후삼조환자적당화혈홍단백여찬전급찬후혈당균경미승고，이도소수평무명현변화，경비교차이균무통계학의의(P>0.05)。결론장신벌타정응용우혈지이상환자，제량여료효밀절상관，교대제량신벌타정구유고효성，단불동제량신벌타정대당대사무명현영향。
Objective To investigate the impact of different doses of simvastatin on glucose metabolism in the treatment of dyslipidemia. Methods One hundred and twenty patients of dyslipidemia were selected in our hospi-tal from January 2012 to August 2014, which were divided into three groups (group A, B, C, with 40 patients in each group) according to random number table. Group A was treated with simvastatin 10 mg daily, group B was treated with 20 mg daily, and group C was treated with 40 mg daily. Changes of lipid levels and blood glucose after treatment (3 months) of the three groups were compared. Results ① The levels of low-density lipoprotein cholesterol (LDL-C) were (2.83±0.52) mmol/L in group A, (2.72±0.49) mmol/L in group B, (1.71±0.32) mmol/L in group C, with statistically significant differences between the three groups (t=6.32, P<0.05). The levels of high-density lipoprotein cholesterol (HDL-C) were (1.26 ± 0.43) mmol/L in group A, (1.32 ± 0.47) mmol/L in group B, (1.36 ± 0.51) mmol/L in group C, with statistically significant differences between the three groups (t=5.78, P<0.05). Total cholesterol (TC) were (4.71±0.40) mmol/L, (4.32±0.31) mmo/L, (3.65±0.35) mmol/L, and triglyceride (TG) were (1.89±0.63) mmol/L, (1.85 ± 0.61) mmol/L, (1.67 ± 0.29) mmol/L, respectively, with statistically significant differences between the three groups (t=4.33, P<0.05). ② The glycosylated hemoglobin (HbAlc), blood sugar levels before and after meal in the three groups were all slightly elevated, and insulin levels showed no significant changes, with no statistically signifi-cant differences between the three groups (P>0.05). Conclusion The dose of simvastatin in treatment of patients with dyslipidemia is closely related to efficacy. Large doses of simvastatin tend to result in higher security and efficien-cy, but different doses of simvastatin has no significant effect on glucose metabolism.
